genomic tests, this genomic analysis. i pathologists here aim to digitise and analyse another a00 slides over the next two years as part of the prospective validation stage of the relapse risk study. to look at the patient s breast cancer tissue, the pathologist places the sample onto a slide, and then embeds it in paraffin wax. this helps both preserve it and keep it in place. then, instead of it being put under a microscope, it s taken from the lab to a digital scanner, where a very high resolution image of the cancerous cells is created. digitising slides isn t a new concept, but running an ai model to determine the risk of cancer returning is. no one involved is suggesting that this will replace the importance of doctors, but the hope is that more detailed data and analysis could enhance theirjudgement calls.
that this will replace the importance of doctors, but the hope is that more detailed data and analysis could enhance theirjudgement calls. here you have the breast cancer that you can see. the thing that is white is fat tissue and the cancer, it s all this stuff which is kind of purple. so, i can see all these details on the slide and check that the quality is good. and once i say, ok, the quality is good, i send it to a server, where the ai is performed. and then, after that, i receive a report performed by the ai, telling me what is the relapse risk associated to this slide. and, after that, i can check the report and also see if, for me, the relapse risk is in accordance with what i saw on the microscope.
could enhance theirjudgement calls. here you have the breast cancer that you can see. the thing that is white is fat tissue and the cancer, it s all this stuff which is kind of purple. so, i can see all these details on the slide and check that the quality is good. and once i say, ok, the quality is good, i send it to a server where the ai is performed. and then, after that, i receive a report performed by the ai, telling me what is the relapse risk associated to this slide. and, after that, i can check the report and also see if, for me, the relapse risk is in accordance with what i saw on the microscope. by the nature of it, it needs to collect a lot of data, and that means it s going to take
digitising slides isn t a new concept, but running an ai model to determine the risk of cancer returning is. no one involved is suggesting that this will replace the importance of doctors, but the hope is that more detailed data and analysis could enhance theirjudgement calls. within minutes of the slides being scanned, the ai will have made its assessment of the risk. in this case, its low, but when it s at a more moderate level, the dilemma really exists. sometimes there is a grey zone and some cases are borderline, so maybe not completely good prognosis, maybe completely bad. and in this grey zone, we need other tools to decide for the prognosis of the patient. and here we have the information that you receive after the al s looked at the data. exactly.
pathologists here aim to digitise and analyse another 400 slides over the next two years, as part of the prospective validation stage of the relapse risk study. to look at the patient s breast cancer tissue, the pathologist places the sample onto a slide, and then embeds it in paraffin wax. this helps both preserve it and keep it in place. then, instead of it being put under a microscope, it s taken from the lab to a digital scanner, where a very high resolution image of the cancerous cells is created. digitising slides isn t a new concept, but running an ai model to determine the risk of cancer returning is. no one involved is suggesting that this will replace the importance of doctors, but the hope is that more detailed data and analysis could enhance theirjudgement calls. within minutes of the slides being scanned, the ai will have